Skip to main content
Open access
Research Article
22 August 2018

Conditional power for assessing population interventions

Abstract

Aim: To calculate conditional power in comparative two-period studies with previously observed baseline data. Method: Isolate the variability attributable to the yet-to-observed data and modify the standard power formulae. Results: For illustration, we examine rates of opioid overdose before and after a reformulation of one opioid product. The null hypothesis posited no impact of the reformulation, alternative hypotheses posited possible impacts, and ancillary hypotheses posited different secular pre-post changes directly observable in comparators. Conditional power varied with the size of the comparator population and with the assumed pre-post change for the comparator. Conclusion: Pre-post designs can be initiated after the baseline period is over. Power calculations that are conditioned on observed baseline data account differently for variability in the baseline and follow-up periods.

Supplementary Material

File (supplementary_information.docx)

References

1.
US Food & Drug Administration. Risk Evaluation and Mitigation Strategies (REMS) (2018). https://www.fda.gov/Drugs/DrugSafety/REMS/default.htm.
2.
Bertrand M, Duflo E, Mullainathan S. How much should we trust differences-in-differences estimates? Quart. J. Econ. 119(1), 249–275 (2004).
3.
Peacock A, Larance B, Bruno R et al. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. Addiction (2018) [Epub ahead of print].
4.
Lachin JM. A review of methods for futility stopping based on conditional power. Stat. Med. 24(18), 2747–2764 (2005).
5.
Alling DW. Early decision in the Wilcoxon two-sample test. J. Am. Stat. Assoc. 58(303), 713–720 (1963).
6.
Lan KK, Wittes J. The B-value: a tool for monitoring data. Biometrics 44(2), 579–585 (1988).
7.
Lan KKG, Simon R, Halperin M. Stochastically curtailed tests in long-term clinical trials. Commun. Stat. C1(3), 207–219 (1982).
8.
Halperin M, Ware J. Early decision in a censored Wilcoxon two-sample test for accumulating survival data. J. Am. Stat. Assoc. 69, 414–422 (1974).
9.
Kittleson JM, Emerson SS. A unifying family of group sequential test designs. Biometrics 55, 874–882 (1999).
10.
Walker AM. Conditional power as an aid in making interim decisions in observational studies. Eur. J. Epidemiol. (2018) [Epub ahead of print].
11.
Wagner AK, Soumerai SB, Zhang F et al. Segmented regression analysis of interrupted time series studies in medication use research. J. Clin. Pharm. Ther. 27(4), 299–309 (2002).
12.
Oakes JM, Feldman HA. Statistical power for nonequivalent pretest-posttest designs. The impact of change-score versus ANCOVA models. Eval. Rev. 25(1), 3–28 (2001).
13.
Agresti A. Categorical Data Analysis. 3rd Edition. John Wiley & Sons, NJ, USA; Section 3.1.7, 73–75 (2013).
14.
IBM Watson. Putting research data into your hands with the MarketScan databases (2017). https://truvenhealth.com/markets/life-sciences/products/data-tools/marketscan-databases.
15.
National Institute of Health. HealthCore data description for NIH Collaboratory distributed research network (2017). https://www.nihcollaboratory.org/Pages/Healthcore-MetaData-Table.aspx.
16.
Green CA, Perrin NA, Janoff SL et al. Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records. Pharmacoepidemiol. Drug Saf. 26(5), 509–517 (2017).
17.
Whitaker HJ, Farrington CP, Spiessens B et al. Tutorial in biostatistics: the self-controlled case series method. Stat. Med. 25(10), 1768–1797 (2006).
18.
Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored, perturbed or curtailed post-event exposures. Biostatistics 10(1), 3–16 (2009).
19.
Farrington P. Censoring on outcome is not valid in self-controlled case series studies. J. Clin. Epidemiol. 66(12), 1428–1429 (2013).
20.
Walker AM. Low power and striking results – a surprise but not a paradox. N. Engl. J. Med. 332(16), 1091–1092 (1995).